Is Isopropylmeprobamate Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Isopropylmeprobamate? Is Isopropylmeprobamate safe for nursing mother and child? Does Isopropylmeprobamate extracts into breast milk? Does Isopropylmeprobamate has any long term or short term side effects on infants? Can Isopropylmeprobamate influence milk supply or can Isopropylmeprobamate decrease milk supply in lactating mothers?
Isopropylmeprobamate lactation summary
- DrLact safety Score for Isopropylmeprobamate is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of Isopropylmeprobamate may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that Isopropylmeprobamate may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of Isopropylmeprobamate low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using Isopropylmeprobamate We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Isopropylmeprobamate usage in lactation
Skeletal muscle relaxant with sedative effects on the central nervous system. It is metabolized to meprobamate.Indicated on low back pain. It is excreted into breast milk in a clinically non-significant amount (Nordeng 2001, Bailey 2002, Briggs 2008) without problems being observed on infants whose mothers were receiving this medication, (Nordeng 2001), except for a mild sedation with higher maternal drug doses (Briggs 2008) .Plasma levels in the infant were undetectable (Briggs 2008). Carisoprodol use increases the risk of abuse and addictive behavior, intoxication and possible psychomotor impairment (Bailey 2002, EMA 2007) being such a reason to be withdrawn from the market in some countries. The European Medicines Agency (EMA) has recommended to withhold authorizations for marketing of medicines that contains Carisoprodol (EMA 2007, Reeves 2012, Bramases 2012). If administered during breastfeeding, it is advisable to use a minimum effective dose and monitor a possible sedation on the infant and an inadequate milk production (Sachs 2013).